Identification

Name
Lormetazepam
Accession Number
DB13872
Type
Small Molecule
Groups
Approved
Description

Lormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia [2]. It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.

Structure
Thumb
Synonyms
  • (±)-Lormetazepam
  • (RS)-Lormetazepam
  • 7-Chloro-1,3-dihydro-5-(o-chlorophenyl)-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one
  • 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one
  • Methyllorazepam
  • N-Methyllorazepam
Categories
UNII
GU56C842ZA
CAS number
848-75-9
Weight
Average: 335.185
Monoisotopic: 334.027583052
Chemical Formula
C16H12Cl2N2O2
InChI Key
FJIKWRGCXUCUIG-UHFFFAOYSA-N
InChI
InChI=1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3
IUPAC Name
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1Cl

Pharmacology

Indication

For the treatment of short-term insomnia [2]

Pharmacodynamics

Lormetazepam is a benzodiazepine which reduces central nervous system (CNS) activity [2, 1]. It produces anxiolytic, muscle relaxant, sedative and hypnotic effects. Because it is a short-acting benzodiapine, it does not produce significant sedation after waking.

Mechanism of action

Lormetazepam, as a benzodiazepine, binds to the regulatory site between the α and γ subunits of γ-aminobutryic acid (GABA) A receptors with γ2 and α1, α2, α3, or α5 subunits [1]. This facilitates the opening of the chloride channel allowing chloride ions to flow into the neuron resulting in hyperpolarization. Hyperpolarized neurons require greater simulation to reach their action potential threshold. The general inhibitory effect on neuronal depolarization produces the effects of lormetazepam.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-2
positive allosteric modulator
Human
AGamma-aminobutyric acid receptor subunit gamma-2
positive allosteric modulator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
positive allosteric modulator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
positive allosteric modulator
Human
AGamma-aminobutyric acid receptor subunit alpha-1
positive allosteric modulator
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Metabolised to an inactive metabolite via glucuronide conjugation [2]

Route of elimination
Not Available
Half life

The terminal phase half life is 11 h [2].

Clearance
Not Available
Toxicity

The primary manifestation of overdosage ranges from drowsiness to coma and symptoms may include ataxia, hypotension, hypotonia, respiratory depression which may lead to death [2].

Experimental LD50 values are as follows [3]: Mouse - 780 mg/kg (intraperitoneal), 1790 mg/kg (oral), 10000 mg/kg (subcutaneous). Rat - 6250 mg/kg (intraperitoneal), 10000 mg/kg (oral), 10000 mg/kg (intraperitoneal).

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Lormetazepam.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Lormetazepam.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Lormetazepam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Lormetazepam.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lormetazepam.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Lormetazepam.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Lormetazepam.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Lormetazepam.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Lormetazepam.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Lormetazepam.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lormetazepam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Lormetazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Amikacin.Approved, Investigational, Vet Approved
AminophyllineThe therapeutic efficacy of Lormetazepam can be decreased when used in combination with Aminophylline.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Lormetazepam.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Lormetazepam.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lormetazepam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lormetazepam.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Lormetazepam.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lormetazepam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Lormetazepam.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Lormetazepam.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Lormetazepam.Investigational, Vet Approved
AzelastineLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Lormetazepam.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Lormetazepam.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Lormetazepam.Approved, Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Lormetazepam.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Lormetazepam.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lormetazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Lormetazepam.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Lormetazepam.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Lormetazepam.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Lormetazepam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lormetazepam.Approved, Investigational
BuprenorphineLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Lormetazepam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lormetazepam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Lormetazepam.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Lormetazepam.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Lormetazepam.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Lormetazepam.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lormetazepam.Approved, Illicit, Vet Approved
CaffeineThe therapeutic efficacy of Lormetazepam can be decreased when used in combination with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Lormetazepam.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Lormetazepam.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Lormetazepam.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Lormetazepam.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Lormetazepam.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Lormetazepam.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Lormetazepam.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lormetazepam.Approved, Illicit, Investigational
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lormetazepam.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lormetazepam.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lormetazepam.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lormetazepam.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lormetazepam.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lormetazepam.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Lormetazepam.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Lormetazepam.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Lormetazepam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Lormetazepam.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Lormetazepam.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Lormetazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Lormetazepam.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Lormetazepam.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lormetazepam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Lormetazepam.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Lormetazepam.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Lormetazepam.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Lormetazepam.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lormetazepam.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Lormetazepam.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Lormetazepam.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lormetazepam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Lormetazepam.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lormetazepam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Lormetazepam.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Lormetazepam.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Lormetazepam.Vet Approved
DeutetrabenazineThe risk or severity of sedation and somnolence can be increased when Lormetazepam is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lormetazepam.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lormetazepam.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Lormetazepam.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lormetazepam.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Lormetazepam.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Lormetazepam.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Lormetazepam.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Lormetazepam.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lormetazepam.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lormetazepam.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lormetazepam.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lormetazepam.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lormetazepam.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lormetazepam.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Lormetazepam.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Lormetazepam.Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Dotarizine.Investigational
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Lormetazepam.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Lormetazepam.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Lormetazepam.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lormetazepam.Approved
DyphyllineThe therapeutic efficacy of Lormetazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Lormetazepam.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Lormetazepam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Lormetazepam.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Lormetazepam.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Lormetazepam.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Lormetazepam.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Eperisone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Lormetazepam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lormetazepam.Approved, Investigational
EthanolLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lormetazepam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lormetazepam.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Lormetazepam.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lormetazepam.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Lormetazepam.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Lormetazepam.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lormetazepam.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Lormetazepam.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Lormetazepam.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Lormetazepam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Lormetazepam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Lormetazepam.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Lormetazepam.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Lormetazepam.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lormetazepam.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lormetazepam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Lormetazepam.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Lormetazepam.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Lormetazepam.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Lormetazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Lormetazepam.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Lormetazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lormetazepam.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lormetazepam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lormetazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lormetazepam.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Lormetazepam.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Lormetazepam.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Lormetazepam.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lormetazepam.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Lormetazepam.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lormetazepam.Approved, Illicit, Investigational
GanciclovirThe therapeutic efficacy of Lormetazepam can be decreased when used in combination with Ganciclovir.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Lormetazepam.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Lormetazepam.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Lormetazepam.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Lormetazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lormetazepam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Lormetazepam.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Lormetazepam.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lormetazepam.Approved
HyaluronidaseThe therapeutic efficacy of Lormetazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lormetazepam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Lormetazepam.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Lormetazepam.Approved
IndalpineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Lormetazepam.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lormetazepam.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lormetazepam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Lormetazepam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Lormetazepam.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lormetazepam.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Lormetazepam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lormetazepam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Lormetazepam.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Lormetazepam.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lormetazepam.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lormetazepam.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lithium is combined with Lormetazepam.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Lormetazepam.Illicit
LofexidineThe therapeutic efficacy of Lormetazepam can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Lormetazepam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Lormetazepam.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lormetazepam.Approved
LorpiprazoleThe risk or severity of sedation can be increased when Lorpiprazole is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lormetazepam.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lormetazepam.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Lormetazepam can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lormetazepam.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Lormetazepam.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Lormetazepam.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Lormetazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Lormetazepam.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Lormetazepam.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Lormetazepam.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lormetazepam.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lormetazepam.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Lormetazepam.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lormetazepam.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Lormetazepam.Approved
MethadoneLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Lormetazepam.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Lormetazepam.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Lormetazepam.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lormetazepam.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Lormetazepam.Approved
MethotrimeprazineLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lormetazepam.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lormetazepam.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Lormetazepam.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lormetazepam.Approved
MetyrosineLormetazepam may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Lormetazepam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved, Investigational
MirtazapineLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Lormetazepam.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Lormetazepam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lormetazepam.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Nefazodone.Approved, Withdrawn
NeomycinThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Neomycin.Approved, Vet Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lormetazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lormetazepam.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Lormetazepam.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Lormetazepam.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lormetazepam.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lormetazepam.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Lormetazepam.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Lormetazepam.Approved, Illicit
OrphenadrineLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Lormetazepam.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lormetazepam.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lormetazepam.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lormetazepam.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lormetazepam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lormetazepam.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lormetazepam.Approved
ParaldehydeLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Lormetazepam.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lormetazepam.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Lormetazepam.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Lormetazepam.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Lormetazepam.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lormetazepam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lormetazepam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Lormetazepam.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Lormetazepam.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lormetazepam.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Lormetazepam.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Lormetazepam.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Lormetazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Lormetazepam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Lormetazepam.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Lormetazepam.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Lormetazepam.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Lormetazepam.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Lormetazepam.Approved
PramipexoleLormetazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Lormetazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Lormetazepam can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Lormetazepam.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Lormetazepam.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Lormetazepam.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lormetazepam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Lormetazepam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Lormetazepam.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Lormetazepam.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lormetazepam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Lormetazepam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Lormetazepam.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lormetazepam.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Lormetazepam.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Lormetazepam.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Pyrantel.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Lormetazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lormetazepam.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Lormetazepam.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Lormetazepam.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Lormetazepam.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lormetazepam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lormetazepam.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Lormetazepam.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Lormetazepam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Lormetazepam.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Rizatriptan.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Lormetazepam.Vet Approved
RopiniroleLormetazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lormetazepam.Approved
RotigotineLormetazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lormetazepam.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lormetazepam.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lormetazepam.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Lormetazepam.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Lormetazepam.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lormetazepam.Approved, Vet Approved
Sodium oxybateLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Lormetazepam.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lormetazepam.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lormetazepam.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Lormetazepam.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Sumatriptan.Approved, Investigational
SuvorexantLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Lormetazepam.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Lormetazepam.Approved, Investigational
TeduglutideThe serum concentration of Lormetazepam can be increased when it is combined with Teduglutide.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Lormetazepam.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lormetazepam.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Lormetazepam.Approved, Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Lormetazepam.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Lormetazepam.Investigational
ThalidomideLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Lormetazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lormetazepam.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Lormetazepam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lormetazepam.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lormetazepam.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Lormetazepam.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Lormetazepam.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Lormetazepam.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Lormetazepam.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Lormetazepam.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lormetazepam.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Lormetazepam.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lormetazepam.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lormetazepam.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Lormetazepam.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Lormetazepam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Lormetazepam.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Lormetazepam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lormetazepam.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Lormetazepam.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Lormetazepam.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Trimethadione.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lormetazepam.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Lormetazepam.Approved
ValaciclovirThe therapeutic efficacy of Lormetazepam can be decreased when used in combination with Valaciclovir.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Lormetazepam.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Lormetazepam.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Lormetazepam.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Lormetazepam.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Lormetazepam.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Lormetazepam.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Lormetazepam.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lormetazepam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Lormetazepam.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Lormetazepam.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Lormetazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Zolmitriptan.Approved, Investigational
ZolpidemLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lormetazepam.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Lormetazepam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Lormetazepam.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lormetazepam.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. 43. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 533-534). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
  2. MRHA: Lormetazepam Summary of Product Characteristics [Link]
  3. ChemIDPlus: Lormetazepam [Link]
External Links
Human Metabolome Database
HMDB0041919
PubChem Compound
13314
PubChem Substance
347829324
ChemSpider
12750
ChEBI
52993
ChEMBL
CHEMBL22097
Wikipedia
Lormetazepam
ATC Codes
N05CD06 — Lormetazepam
MSDS
Download (49.8 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0164 mg/mLALOGPS
logP2.92ALOGPS
logP3.39ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)10.68ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.9 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity85.82 m3·mol-1ChemAxon
Polarizability32.21 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-1219000000-503deaa645713d28cd79
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-2739000000-db8dc59f3b0cd2b1f961
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives / Chlorobenzenes / Aryl chlorides / Tertiary carboxylic acid amides / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Alkanolamines / Organopnictogen compounds
show 4 more
Substituents
1,4-benzodiazepine / Alpha-amino acid or derivatives / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Tertiary carboxylic acid amide / Carboxamide group
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organochlorine compound, 1,4-benzodiazepinone (CHEBI:52993)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
Curator comments
Facilitates opening of the chloride channel.
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Rang, H. P. and Dale, M. M. (2012). Rang and Dale's Pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
Curator comments
Facilitates opening of the chloride channel.
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRG2
Uniprot ID
P18507
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-2
Molecular Weight
54161.78 Da
References
  1. Rang, H. P. and Dale, M. M. (2012). Rang and Dale's Pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
Curator comments
Facilitates opening of the chloride channel.
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Rang, H. P. and Dale, M. M. (2012). Rang and Dale's Pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
Curator comments
Facilitates opening of the chloride channel.
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Rang, H. P. and Dale, M. M. (2012). Rang and Dale's Pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
Curator comments
Facilitates opening of the chloride channel.
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Rang, H. P. and Dale, M. M. (2012). Rang and Dale's Pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]

Drug created on July 07, 2017 15:36 / Updated on August 02, 2018 07:00